Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment

NCT02680041 is registered in ClinicalTrials.gov with Blue Earth Diagnostics as lead sponsor.

NCT NCT02680041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02680041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment
Lead sponsor
Blue Earth Diagnostics
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2016
Completion date
November 1, 2017
Enrollment
221 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer